Dendreon Corporation (Nasdaq: DNDN) announced significant milestones that support broad availability for on-label use of PROVENGE® (sipuleucel-T), the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer (mCRPC).
To view Multimedia News Release, go to http://www.multivu.com/mnr/50924-dendreon-provenge-cellular-immunotherapy
The Sanford Guide, recognized as the essential reference for infectious disease treatment, announced the release of its first mobile app for the iPhone, iPod touch and iPad. The Sanford Guide App, available on Apple’s App Store for $29.99, contains the comprehensive guidelines and recommendations featured in the well-known pocket-size guides used by health care professionals in treatment decision making for over 40 years.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/sanfordguide/50808/
On October 21st, 2011, Lancôme invites customers to experience the “Beauty of Giving” by celebrating Genes Day, a one-day national event Lancôme began in 2010 to support St. Jude Children’s Research Hospital, one of the world’s premier centers for the research and treatment of pediatric cancer and other catastrophic childhood diseases. On this day, Lancôme will donate $7 from the sale of every bottle of Génifique Youth Activating Concentrate to St. Jude. (This is in addition to special promotions and events nationwide surrounding Genes Day throughout the month of October.)
To view Multimedia News Release, go to http://www.multivu.com/mnr/52300-lancome-genes-day-2011-st-jude-julia-roberts-genifique-beauty-of-giving
Famed dancer, actress, and director Debbie Allen has teamed up with Medtronic, Inc. (NYSE: MDT) today to kick off “Join the Pace Makers,” a national campaign designed to empower people with a condition called bradycardia, also known as a slow heartbeat, to learn about their available treatment options so that they can have an informed conversation with their doctor.
People living with bradycardia can experience a number of symptoms ranging from general lethargy and shortness of breath to fainting or syncope. There are a number of treatment options available, including medication therapy and implanting a pacemaker, which delivers electrical pulses to help regulate a person’s heartbeat.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52990-debbie-allen-and-medtronic-join-the-pace-makers
It’s not every day a 75-year-old company re-defines its brand icon. Water treatment leader Culligan International is doing just that with an update to its famous “Hey Culligan Man!” persona. A new website at culligan.com (culligan.ca in Canada) features a new Culligan Man and is loaded with information on water quality and water treatment solutions for homeowners and businesses. The initiatives cap the company’s 75th anniversary year.
Introduced in 1958, “Hey, Culligan Man!” remains one of the most recognized advertising slogans and an important link between customers and the company’s network of over 800 dealers in 90 countries worldwide.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53999-culligan-celebrates-75-years-with-hey-culligan-man-update-and-new-website
Miramar Labs today announced that the miraDry System for the treatment of primary axillary hyperhidrosis, commonly known as excessive underarm sweat, is now available to select physicians in the U.S. The miraDry procedure provides a safe and lasting solution for this debilitating condition.
The U.S. Food & Drug Administration granted clearance for miraDry following a robust, randomized, blinded clinical study that involved 120 patients at seven clinics and followed them 12-months post treatment. The miraDry System delivers energy non-invasively to the area under the arm where the sweat glands reside which creates localized heat to destroy and eliminate the glands. Since sweat glands do not regenerate, results are lasting.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54021-miramar-labs-miradry-treat-excessive-underarm-sweat-axillary-hyperhidrosis
Approximately 80 million American men and women experience some form of hair loss. Premature balding or thinning hair can often result in a decrease of self esteem. Freedom Laser Therapy of Los Angeles is dedicated to change all that by bringing their iRestore Hair Rejuvenation System to the mass market.
This proven, safe Laser Hair Restoration Technology, otherwise known as phototherapy, is a scientific process providing stimulation to cells in your hair. The 25-year old advanced low-level laser treatment stimulates the scalp, allowing miniaturized and dormant hair follicles to rejuvenate.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54394-freedom-laser-therapy-laser-hair-treatment-regrowth-restoration
With the official arrival of spring and the official start to flea and tick season, PetArmor® has teamed up with the ASPCA® (The American Society for the Prevention of Cruelty to Animals®) and shelter animal advocate and PetArmor® spokesperson Amy Smart to launch the PetArmor® Protection Promise. The national campaign elevates the ongoing commitment PetArmor® and the ASPCAshare to protect pets in need. PetArmor® is the No. 1 selling fipronil generic flea and tick treatment. PetArmor® has the same No. 1 veterinarian recommended active ingredient and offers the same flea and tick protection as Frontline® Top Spot® at about half the cost. The PetArmor® Protection Promise offers pet lovers and dog and cat owners an opportunity to help pets in need, especially those in shelters across the country.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55464-amy-smart-petarmor-aspca-launch-protection-promise-healthcare-for-all-pets
Today the Confederation of Meningitis Organisations (CoMO) is urging people all over the world to “Join Hands Against Meningitis” in an effort to reduce the global impact of the disease. The call-to-action encourages individuals, families and communities to learn the signs and symptoms of meningitis, the importance of urgent treatment of the disease, and that prevention is available through vaccination against some forms of meningitis.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55808-world-meningitis-day-join-the-fight-to-stop-meningitis
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
New recommendations from the American Society of Clinical Rheumatologists (ASCR), published in Postgraduate Medicine, highlight updated management recommendations for patients with acute gout. These new recommendations come at a time when the incidence of gout is soaring; 8.3 million Americans are estimated to be gout patients.
Instead of challenging, restrictive dieting, patients are encouraged to consume a balanced diet of fresh fruit and vegetables, low-fat dairy products, nuts and grains. More importantly, patients should limit their intake of high fructose corn syrup, a common ingredient in many processed foods and drinks, and purine-rich foods, particularly red meat, beer and shellfish.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56234-gout-uric-acid-education-arthritis-lifestyle-change-treatment-options
